Parameter
| Biomarker | PD-L1 (Programmed death ligand 1) | Full name | Programmed death-ligand 1 | Molecular Type | Proteins |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction, prognosis | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissue (IHC, e.g. 28-8, SP142 antibody), circulating tumor cells (CTC, flow cytometry) | ||
| Pathobiological Mechanisms | The high expression of PD-L1 in gastric cancer cells binds to PD-1 on the surface of T cells to inhibit the killing function of T cells and achieve immune escape. The expression level of PD-L1 is positively correlated with the efficacy of immune checkpoint inhibitors (ICIs) | ||||
| Clinical Availability Status | Clinical usability (immunotherapy screening) : guidelines recommend it for screening patients with ICIs treatment, and the cutoff values of different antibodies (28-8 and SP142) are different | ||||
| Notes and Dynamics | Ebv-positive and MSI-H/dMMR gastric cancer are the core predictive markers of immunotherapy, the PD-L1 expression rate is higher, and the combination of CTLA-4 inhibitors can improve the efficacy. Dynamic monitoring of PD-L1 expression can guide the adjustment of immunotherapy course, which is the key indicator for accurate screening of immunotherapy in gastric cancer | ||||